Last reviewed · How we verify
NCT06641583: LEGO
Efficacy of LEGO Therapy for Adolescent With Level 1 Autism
NA trial testing LEGO in Neurodevelopmental Disorder in 50 participants. Completed in 31 December 2025.
31 December 2025
Quick facts
| Lead sponsor | Antonio Narzisi |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 20 September 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- LEGO
- Controllo
Conditions studied
- Neurodevelopmental Disorder — all drugs for Neurodevelopmental Disorder →
Sponsor
Antonio Narzisi
Who can join
Adults 10 to 14, any sex, with Neurodevelopmental Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn if LEGO therapy can enhance social skills in children aged 10-14 diagnosed with high-functioning Autism Spectrum Disorder. The main questions it aims to answer are: Does LEGO therapy improve social communication and interaction skills in children with Autism Spectrum Disorder? Do children show behavioral improvements in social skills after participating in LEGO therapy? Researchers will compare children receiving LEGO therapy to a control group (who will not receive LEGO therapy but continue their usual treatments) to see if LEGO therapy leads to greater improvements in social skills. Participants will: Complete behavioral tasks, including a LEGO construction test, at the beginning (T0) and after 3 months (T1). Attend weekly LEGO therapy sessions for 90 minutes, over the course of 3 months (12 sessions). Complete questionnaires about social behaviors, both parents and children, at T0 and T1.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06641583
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neurodevelopmental Disorder
Currently open trials in the same condition.
- NCT06828822 — CongenItal Naevus Cohort for Longitudinal Evaluation · NA · recruiting
- NCT06690151 — Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal · recruiting
- NCT06613126 — Effectiveness of Symptom Management Application on Parental Care Ability of Children With Tourette Syndrome · NA · recruiting
- NCT06442592 — Characterization and Support for Neurodevelopmental Disorders Associated With Congenital Heart Defects · NA · recruiting
- NCT01778504 — Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06641583 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Antonio Narzisi
- Last refreshed: 1 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06641583.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing